483
Biomat USA IncFDA 483 - Biomat USA Inc - March 07, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Bio-Blood Components Inc in Columbus, OH, a source plasma establishment, revealed two significant observations. These included inadequate preparation of phlebotomy sites, leading to concerns about sterility, and a failure to timely submit multiple biological product deviation reports. These issues indicate potential non-compliance with regulations concerning donor safety and reporting requirements.
- Person
Open in Dashboard
ID · f8c8757c-7756-4fad-89de-94e1fdad012a